Acetylon Pharmaceuticals’ Selective HDAC Inhibitors in Multiple Myeloma, Lymphoma and Sickle Cell Disease and β-Thalassemia

  Acetylon Pharmaceuticals’ Selective HDAC Inhibitors in Multiple Myeloma,
  Lymphoma and Sickle Cell Disease and β-Thalassemia to Be Featured in 11
  Presentations at the American Society of Hematology Annual Meeting

-- Presentations Include Interim Updates from Two Clinical Trials of ACY-1215
       for the Treatment of Relapsed or Refractory Multiple Myeloma --

ASH 2013

Business Wire

BOSTON -- November 25, 2013

Acetylon Pharmaceuticals, Inc., the leader in the development of selective
histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, today
announced that its selective HDAC inhibitor drug candidates will be the
subject of eleven presentations, including three oral presentations and eight
poster presentations of preclinical and clinical research in multiple myeloma,
lymphoma and sickle cell disease/β-thalassemia at the American Society of
Hematology (ASH) Annual Meeting to be held December 7-10, 2013, in New
Orleans, LA. The presentations will include interim updates of two clinical
trials of ACY-1215, a selective HDAC6 inhibitor: a Phase 1/2 trial in
combination with bortezomib and dexamethasone and a Phase 1b trial in
combination with lenalidomide and dexamethasone for the treatment of relapsed
or refractory multiple myeloma. In addition, Acetylon and scientific
collaborators will present results of preclinical studies of ACY-1215,
demonstrating potent combination treatment in disease models of multiple
myeloma and lymphoma, along with preclinical studies of its selective HDAC1/2
inhibitors in sickle cell disease and β-thalassemia.

Details of the presentations are as follows:

Multiple Myeloma

Oral Presentation
Date: Monday, December 9, 2013
Time: 6:15-7:45pm CT
Location: 393-394
Session: 653. Myeloma: Therapy, excluding Transplantation: Advances in
Multiple Myeloma and Plasma Cell Leukemia
Abstract #: 759
Title: ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim
Results of Combination Therapy with Bortezomib in Patients with Multiple
Myeloma (MM)


Poster Presentations
Date: Saturday, December 7, 2013
Time: 5:30-7:30pm CT
Location: Hall G
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I
Abstract #: 1952
Title: ACY-1215, a First-In-Class Selective Inhibitor of HDAC6, Demonstrates
Significant Synergy with Immunomodulatory Drugs (IMiDs) in Preclinical Models
of Multiple Myeloma


Date: Saturday, December 7, 2013
Time: 5:30-7:30pm CT
Location: Hall G
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster
I
Abstract #: 1909
Title: Discovery Histone Deacetylase (HDAC)6 Specific Proteomic Biomarkers in
Multiple Myeloma (MM) Using Stable Isotope Labeling by Amino Acids in Cell
Culture (SILAC)


Date: Sunday, December 8, 2013
Time: 6:30-8:30pm CT
Location: Hall G
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II
Abstract #: 3190
Title: ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor, in
Combination with Lenalidomide and Dexamethasone (dex), is Well Tolerated
Without Dose Limiting Toxicity (DLT) in Patients with Multiple Myeloma at
Doses Demonstrating Biologic Activity: Interim Results of a Phase 1b Trial


Date: Sunday, December 8, 2013
Time: 6:30-8:30pm CT
Location: Hall G
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II
Abstract #: 3219
Title: Tubulin Hyper-Acetylation in Blood Lymphocytes: Pharmacodynamic (PD)
Biomarker for the Selective Histone Deacetylase (HDAC) 6 Inhibitor ACY-1215 in
Multiple Myeloma Patients


Date: Monday, December 9, 2013
Time: 6:00-8:00pm CT
Location: Hall G
Session: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding
Therapy: Poster III
Abstract #: 4437
Title: Preclinical Combination of the Oral Investigational Agents ACY-1215, a
Selective HDAC6 Inhibitor, and Ixazomib, a Proteasome Inhibitor, Demonstrates
Combination Benefit in Multiple Myeloma Cell Lines and Xenograft Models


Date: Monday, December 9, 2013
Time: 6:00-8:00pm CT
Location: Hall G
Session: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding
Therapy: Poster III
Abstract #: 4431
Title: Inhibition of Autophagy by ACY-1215, a Selective HDAC6 Inhibitor,
Accelerates Carfilzomib-Induced Cell Death in Multiple Myeloma


Lymphoma

Oral Presentation
Date: Monday, December 9, 2013
Time: 4:30-6:30pm CT
Location: 220-222
Session: 625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Small
Molecule Targets in Lymphoma
Abstract #: 648
Title: Dual Targeting with the Selective Histone Deacetylase (HDAC) 6
Inhibitor, ACY-1215, and Bortezomib (BOR) Leads to Marked Disruption of
Protein Degradation Pathways and Apoptosis in Preclinical Models of Lymphoma


Poster Presentation
Date: Sunday, December 8, 2013
Time: 6:30-8:30pm CT
Location: Hall G
Session: 625. Lymphoma: Preclinical – Chemotherapy and Biologic Agents: Poster
II
Abstract #: 3071
Title: Inhibition of HDAC6 in Combination with Targeted Agents Results in
Broad Synergistic Decreases in Viability in Non-Hodgkin’s Lymphoma (NHL) Cells


Sickle Cell Disease/β-Thalassemia

Oral Presentation
Date: Monday, December 9, 2013
Time: 4:30-6:00pm CT
Location: 343-345
Session: 112. Thalassemia and Globin Gene Regulation: Preclinical and Clinical
Therapeutic Strategies for Thalassemia
Abstract #: 564
Title: Pharmacological Inhibition of Histone Deacetylase (HDAC) 1, 2 or 3 have
Distinct Effects on Cellular Viability, Erythroid Differentiation, and Fetal
Globin (HbG) Induction


Poster Presentation
Date: Sunday, December 8, 2013
Time: 6:30-8:30pm CT
Location: Hall E
Session: 112. Thalassemia and Globin Gene Regulation: Poster II
Abstract #: 2253
Title: Mechanistic Insights into Fetal Hemoglobin (HbF) Induction Through
Chemical Inhibition of Histone Deacetylase 1 and 2 (HDAC1/2)


About Acetylon

Acetylon Pharmaceuticals, Inc., based in Boston, Massachusetts, is a leader in
the development of novel small molecule drugs targeting epigenetic mechanisms
for the enhancement of therapeutic outcomes in cancer and other critical human
diseases. The Company’s epigenetic drug discovery platform has yielded a
proprietary portfolio of optimized, orally-administered Class I and Class II
histone deacetylase (HDAC) selective compounds. Alteration of HDAC regulation
through selective HDAC inhibition is thought to be applicable to a broad range
of diseases including cancer, sickle cell disease and beta-thalassemia, and
autoimmune and neurodegenerative diseases. Acetylon’s lead drug candidate,
ACY-1215, is a selective HDAC6 inhibitor currently in Phase 1b clinical
development for the treatment of multiple myeloma. The Company recently
announced a strategic collaboration agreement with Celgene Corporation, which
includes an exclusive option for the future acquisition of Acetylon by
Celgene. Acetylon’s scientific founders are affiliated with the Harvard
University, the Dana-Farber Cancer Institute, the Massachusetts General
Hospital, the Broad Institute and Harvard Medical School. www.acetylon.com

Contact:

Acetylon
Walter C. Ogier, 617-245-1300
President and Chief Executive Officer
wogier@acetylon.com
or
Media:
MacDougall Biomedical Communications
Kari Watson, 781-235-3060
kwatson@macbiocom.com
or
Michelle Avery, 781-235-3060
mavery@macbiocom.com
 
Press spacebar to pause and continue. Press esc to stop.